Is NewAmsterdam Pharma Co N.V. (NAMSW) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| DJIM | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| MSCI | 0.0% / 33% | 82.7% / 33% | 3.0% / 33% | 122.61% / 5% | ✗ NOT HALAL |
| S&P | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| FTSE | 0.0% / 33% | 82.7% / 33% | 3.0% / 50% | 122.61% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -206187.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -28.3% | |
| Return on Assets (ROA) | -17.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$148M |
| Free Cash Flow | -$148M |
| Total Debt | $202,000 |
| Debt-to-Equity | 0.0 |
| Current Ratio | 7.9 |
| Total Assets | $769M |
Price & Trading
| Last Close | $20.07 |
| 50-Day MA | $21.37 |
| 200-Day MA | $19.13 |
| Avg Volume | 708 |
| Beta | 0.1 |
|
52-Week Range
$5.45
| |
About NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Related Halal Stocks in
Frequently Asked Questions
Is NewAmsterdam Pharma Co N.V. (NAMSW) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NewAmsterdam Pharma Co N.V. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NewAmsterdam Pharma Co N.V.'s debt ratio?
NewAmsterdam Pharma Co N.V.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are NewAmsterdam Pharma Co N.V.'s key financial metrics?
NewAmsterdam Pharma Co N.V. has a market capitalization of N/A, and revenue of $23M. Return on equity stands at -28.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.